Edward Bradley, MD

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.